TIA1 and in situ carcinoma: In carcinoma in situ and advanced cancers, TIA1 staining was observed in both the cytoplasm and the nucleus, and cytoplasmic TIA1 immunoreactivity was higher in advanced cancers than in carcinoma in situ.